We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Instrumentation Laboratory, Inova Diagnostics and Biokit Organizationally Transform and Now Share Werfen Name

By LabMedica International staff writers
Posted on 13 Jul 2021
Werfen (Barcelona, Spain) companies, including Instrumentation Laboratory (IL), Inova Diagnostics (Inova), and Biokit, are uniting under one name and one brand - Werfen. More...
As part of this effort, the company has completed organizational transitions and adopted a new global brand identity, including a new corporate logo.

While IL, Inova and Biokit have been part of Werfen since 1992, 2009, and 1973, respectively, they will now be known simply as Werfen. The company has been known as Werfen outside of North America since 2014. The strategic hubs for the Company's key business lines will now be led by Chief Operating Officers, and operate as Werfen Headquarters and Technology Centers. Management and organization of Werfen's Commercial Operations in North America will now be consolidated. Field Service and Customer Service functions will be unified across business lines, while Sales, Applications, Marketing and Technical Support will remain specialized.

With a new logo and brand colors, Werfen adopts a new brand identity - evoking innovation and humanity. The new Werfen logo is modern, strong and singular, signifying unity in the company's quest to deliver innovation after innovation, for every patient whose life could depend upon the quality of a test result. The new logo will be incorporated into the company's products and communication vehicles gradually, over time. The legal names for IL, Inova and Biokit, and any contracts or purchasing agreements, are unaffected by this change.

"This transformation represents a natural evolution for Werfen, strengthening our global leadership position in specialized diagnostics, and positively impacting our ability to drive innovation and support our customers," said Carlos Pascual, CEO at Werfen. "By sharing one global identity, with the same vision and strategic objectives, our teams around the world will maximize collaboration to set new standards for products and services in Hemostasis, Acute Care, Autoimmunity and OEM diagnostics."

Related Links:
Werfen


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gold Member
Hybrid Pipette
SWITCH
Human Estradiol Assay
Human Estradiol CLIA Kit
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: Development of targeted therapeutics and diagnostics for extrapulmonary tuberculosis at University Hospital Cologne (Photo courtesy of Michael Wodak/Uniklinik Köln)

Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.